Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STP705 Dose Escalation in isSCC
NCT04293679Phase 2Completed
- Sponsor
- Sirnaomics
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of sirna-tgf-b1 + sirna-cox-2 in cutaneous squamous cell carcinoma in situ (SCCIS), sponsored by Sirnaomics. Started Mar 2019; status: completed.
02
Drugs
sirna-tgf-b1 + sirna-cox-2
03
Conditions
cutaneous squamous cell carcinoma in situ (SCCIS)
Beyond the preview
Go deeper on NCT04293679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04293679.